Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Wet Macular Degeneration: later-stage trial registry
A small indexed set (5 trials) with no open enrollment listed right now.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · none currently recruiting · #3,391 of 28,707 conditions by registered trial count
Wet Macular Degeneration: 5 US clinical trials tracked, none currently recruiting.
Wet Macular Degeneration is the subject of 5 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 5 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Outlook Therapeutics, running 3 of these trials.
Enrollment posture brief
Registry condition wet-macular-degeneration
OPEN 0 | RECR 0% | LATE 5 | EARLY 0 | RANK #3391 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Wet Macular Degeneration has no open enrollment in this registry pull (5 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Wet Macular Degeneration on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Wet Macular Degeneration is recruiting below its size-band peers.
0 of 5 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Wet Macular Degeneration research.
Outlook Therapeutics accounts for 3 of 5 trials (60%). 3 distinct sponsors appear on at least one study for this condition label.
-
Typical Wet Macular Degeneration enrolment sits around 195 participants.
Median target enrolment is 195 among the 5 trials that report a genuine target (sentinel values excluded). 1 of those (20%) plan for fewer than 100 participants.
-
Wet Macular Degeneration research is mostly interventional.
5 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Indexed trials (enrollment closed)
5 total, page 1 of 1
A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders
Outlook Therapeutics
NCT05112861
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)
Hoffmann-La Roche
NCT03823287
A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
Outlook Therapeutics
NCT03834753
A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders
Outlook Therapeutics
NCT04516278
Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMD
Novartis Pharmaceuticals
NCT03954626
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 5 |
Top Sponsors
Named interventions
Most-linked intervention names on Wet Macular Degeneration records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Wet Macular Degeneration trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Wet Macular Degeneration page
5 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Wet Macular Degeneration trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Outlook Therapeutics sponsors the most Wet Macular Degeneration trials on record, review their full trial history before evaluating a specific study. See Outlook Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Wet Macular Degeneration condition card totals 5 registered trials; most-linked intervention bevacizumab; top US site state Arizona. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.